Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

5

US Approved Rx

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Advanced glycation end products

5

Carbonyl stress

5

lipid oxidation

5

pyridoxamine 5'-phosphate oxidase

5

reactive oxygen species metabolic process

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase III

5

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

5

1947

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Diabetic nephropathy

5

Schizophrenia

5

Unknown

5

Pyridoxine deficiency

3

Pyridoxine-dependent epilepsy

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

8

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

5

CNS Active

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Snell, E.

5

Wm. S. Merrell

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

8

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

8

EPA CompTox

8

FDA UNII

8

PUBCHEM

8

SMS_ID

8

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

1

ANTIINFECTIVES FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIMYCOBACTERIALS

1

VITAMINS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DRUGS FOR TREATMENT OF TUBERCULOSIS

1

OTHER PLAIN VITAMIN PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Combinations of drugs for treatment of tuberculosis

1

Other plain vitamin preparations

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

6

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 8 of 8 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

PYRIDOXINE

KV2JZ1BI6Z

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1947

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Alpha-1-antichymotrypsin

Oxidative Stress

Conditions:

Pyridoxine deficiency

Pyridoxine-dependent epilepsy

Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Vitamin B6 (pyridoxine) is a water-soluble vitamin used in the prophylaxis and treatment of vitamin B6 deficiency and peripheral neuropathy in thos...

e receiving isoniazid (isonicotinic acid hydrazide, INH). Vitamin B6 has been found to lower systolic and diastolic blood pressure in a small group of subjects with essential hypertension. Hypertension is another risk factor for atherosclerosis and coronary heart disease. Another study showed pyridoxine hydrochloride to inhibit ADP- or epinephrine-induced platelet aggregation and to lower total cholesterol levels and increase HDL-cholesterol levels, again in a small group of subjects. Vitamin B6, in the form of pyridoxal 5'-phosphate, was found to protect vascular endothelial cells in culture from injury by activated platelets. Endothelial injury and dysfunction are critical initiating events in the pathogenesis of atherosclerosis. Human studies have demonstrated that vitamin B6 deficiency affects cellular and humoral responses of the immune system. Vitamin B6 deficiency results in altered lymphocyte differentiation and maturation, reduced delayed-type hypersensitivity (DTH) responses, impaired antibody production, decreased lymphocyte proliferation and decreased interleukin (IL)-2 production, among other immunologic activities. Used for the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy.

PYRIDOXAMINE

6466NM3W93

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

pyridoxamine 5'-phosphate oxidase

reactive oxygen species metabolic process

Advanced glycation end products

Carbonyl stress

lipid oxidation

Conditions:

Diabetic nephropathy

Pyridoxamine (PM) is one of three natural forms of vitamin B6. It is a critical transient intermediate in catalysis of transamination reactions by vitamin B6-dependent enzymes. In preclinical or clinical trials PM has demonstrated pharmacological pot...

ential for treatment of diabetic nephropathy, diabetic retinopathy, and hyperlipidemia, and for use in kidney stone preventive therapies. Although its precise mode of action in vivo is not yet clear, it is likely that at least three mechanisms are at play: inhibition of post-Amadori steps of the Maillard reaction; scavenging of reactive carbonyl compounds; and inhibition of toxic effects of ROS. Pyridoxamine was marketed as a dietary supplement, often as the hydrochloride salt, pyridoxamine dihydrochloride. However, in the United States, the FDA ruled in January 2009 that pyridoxamine must be regulated as a pharmaceutical drug because it is the active ingredient in Pyridorin, a drug designed to prevent the progression of diabetic nephropathy.

PYRIDOXINE DIPALMITATE

HB49XCT029

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1947

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Alpha-1-antichymotrypsin

Oxidative Stress

Conditions:

Pyridoxine deficiency

Pyridoxine-dependent epilepsy

Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Vitamin B6 (pyridoxine) is a water-soluble vitamin used in the prophylaxis and treatment of vitamin B6 deficiency and peripheral neuropathy in thos...

e receiving isoniazid (isonicotinic acid hydrazide, INH). Vitamin B6 has been found to lower systolic and diastolic blood pressure in a small group of subjects with essential hypertension. Hypertension is another risk factor for atherosclerosis and coronary heart disease. Another study showed pyridoxine hydrochloride to inhibit ADP- or epinephrine-induced platelet aggregation and to lower total cholesterol levels and increase HDL-cholesterol levels, again in a small group of subjects. Vitamin B6, in the form of pyridoxal 5'-phosphate, was found to protect vascular endothelial cells in culture from injury by activated platelets. Endothelial injury and dysfunction are critical initiating events in the pathogenesis of atherosclerosis. Human studies have demonstrated that vitamin B6 deficiency affects cellular and humoral responses of the immune system. Vitamin B6 deficiency results in altered lymphocyte differentiation and maturation, reduced delayed-type hypersensitivity (DTH) responses, impaired antibody production, decreased lymphocyte proliferation and decreased interleukin (IL)-2 production, among other immunologic activities. Used for the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy.

PYRIDOXINE HYDROCHLORIDE

68Y4CF58BV

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1947

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Alpha-1-antichymotrypsin

Oxidative Stress

Conditions:

Pyridoxine deficiency

Pyridoxine-dependent epilepsy

Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Vitamin B6 (pyridoxine) is a water-soluble vitamin used in the prophylaxis and treatment of vitamin B6 deficiency and peripheral neuropathy in thos...

e receiving isoniazid (isonicotinic acid hydrazide, INH). Vitamin B6 has been found to lower systolic and diastolic blood pressure in a small group of subjects with essential hypertension. Hypertension is another risk factor for atherosclerosis and coronary heart disease. Another study showed pyridoxine hydrochloride to inhibit ADP- or epinephrine-induced platelet aggregation and to lower total cholesterol levels and increase HDL-cholesterol levels, again in a small group of subjects. Vitamin B6, in the form of pyridoxal 5'-phosphate, was found to protect vascular endothelial cells in culture from injury by activated platelets. Endothelial injury and dysfunction are critical initiating events in the pathogenesis of atherosclerosis. Human studies have demonstrated that vitamin B6 deficiency affects cellular and humoral responses of the immune system. Vitamin B6 deficiency results in altered lymphocyte differentiation and maturation, reduced delayed-type hypersensitivity (DTH) responses, impaired antibody production, decreased lymphocyte proliferation and decreased interleukin (IL)-2 production, among other immunologic activities. Used for the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy.

PYRIDOXAMINE HYDROCHLORIDE

58WN04G9K9

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

pyridoxamine 5'-phosphate oxidase

reactive oxygen species metabolic process

Advanced glycation end products

Carbonyl stress

lipid oxidation

Conditions:

Diabetic nephropathy

Pyridoxamine (PM) is one of three natural forms of vitamin B6. It is a critical transient intermediate in catalysis of transamination reactions by vitamin B6-dependent enzymes. In preclinical or clinical trials PM has demonstrated pharmacological pot...

ential for treatment of diabetic nephropathy, diabetic retinopathy, and hyperlipidemia, and for use in kidney stone preventive therapies. Although its precise mode of action in vivo is not yet clear, it is likely that at least three mechanisms are at play: inhibition of post-Amadori steps of the Maillard reaction; scavenging of reactive carbonyl compounds; and inhibition of toxic effects of ROS. Pyridoxamine was marketed as a dietary supplement, often as the hydrochloride salt, pyridoxamine dihydrochloride. However, in the United States, the FDA ruled in January 2009 that pyridoxamine must be regulated as a pharmaceutical drug because it is the active ingredient in Pyridorin, a drug designed to prevent the progression of diabetic nephropathy.

PYRIDOXAMINE PHOSPHATE ANHYDROUS

Q05R77UO7P

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

pyridoxamine 5'-phosphate oxidase

reactive oxygen species metabolic process

Advanced glycation end products

Carbonyl stress

lipid oxidation

Conditions:

Diabetic nephropathy

Pyridoxamine (PM) is one of three natural forms of vitamin B6. It is a critical transient intermediate in catalysis of transamination reactions by vitamin B6-dependent enzymes. In preclinical or clinical trials PM has demonstrated pharmacological pot...

ential for treatment of diabetic nephropathy, diabetic retinopathy, and hyperlipidemia, and for use in kidney stone preventive therapies. Although its precise mode of action in vivo is not yet clear, it is likely that at least three mechanisms are at play: inhibition of post-Amadori steps of the Maillard reaction; scavenging of reactive carbonyl compounds; and inhibition of toxic effects of ROS. Pyridoxamine was marketed as a dietary supplement, often as the hydrochloride salt, pyridoxamine dihydrochloride. However, in the United States, the FDA ruled in January 2009 that pyridoxamine must be regulated as a pharmaceutical drug because it is the active ingredient in Pyridorin, a drug designed to prevent the progression of diabetic nephropathy.

PYRIDOXAMINE PHOSPHATE

QWW7V29814

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

pyridoxamine 5'-phosphate oxidase

reactive oxygen species metabolic process

Advanced glycation end products

Carbonyl stress

lipid oxidation

Conditions:

Diabetic nephropathy

Pyridoxamine (PM) is one of three natural forms of vitamin B6. It is a critical transient intermediate in catalysis of transamination reactions by vitamin B6-dependent enzymes. In preclinical or clinical trials PM has demonstrated pharmacological pot...

ential for treatment of diabetic nephropathy, diabetic retinopathy, and hyperlipidemia, and for use in kidney stone preventive therapies. Although its precise mode of action in vivo is not yet clear, it is likely that at least three mechanisms are at play: inhibition of post-Amadori steps of the Maillard reaction; scavenging of reactive carbonyl compounds; and inhibition of toxic effects of ROS. Pyridoxamine was marketed as a dietary supplement, often as the hydrochloride salt, pyridoxamine dihydrochloride. However, in the United States, the FDA ruled in January 2009 that pyridoxamine must be regulated as a pharmaceutical drug because it is the active ingredient in Pyridorin, a drug designed to prevent the progression of diabetic nephropathy.

PYRIDOXAMINE DIHYDROCHLORIDE

YQ8NCR7V0O

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

pyridoxamine 5'-phosphate oxidase

reactive oxygen species metabolic process

Advanced glycation end products

Carbonyl stress

lipid oxidation

Conditions:

Diabetic nephropathy

Pyridoxamine (PM) is one of three natural forms of vitamin B6. It is a critical transient intermediate in catalysis of transamination reactions by vitamin B6-dependent enzymes. In preclinical or clinical trials PM has demonstrated pharmacological pot...

ential for treatment of diabetic nephropathy, diabetic retinopathy, and hyperlipidemia, and for use in kidney stone preventive therapies. Although its precise mode of action in vivo is not yet clear, it is likely that at least three mechanisms are at play: inhibition of post-Amadori steps of the Maillard reaction; scavenging of reactive carbonyl compounds; and inhibition of toxic effects of ROS. Pyridoxamine was marketed as a dietary supplement, often as the hydrochloride salt, pyridoxamine dihydrochloride. However, in the United States, the FDA ruled in January 2009 that pyridoxamine must be regulated as a pharmaceutical drug because it is the active ingredient in Pyridorin, a drug designed to prevent the progression of diabetic nephropathy.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1